Perceptive Advisors led a $55m round for Ionis-backed rare disease drug developer Dynacure following a 2018 round that was the same size.
Dynacure, a France-based muscular disease drug developer backed by RNA-focused pharmaceutical company Ionis Pharmaceuticals, completed a €50m ($55m) series C round on Wednesday.
The round was led by investment firm Perceptive Advisors and included state-owned investment bank BPIfrance’s Large Venture, Fabs and Fonds Biothérapies Innovantes et Maladies Rares funds, in addition to Andera Partners, Kurma Partners, Pontifax and unnamed funds managed by Tekla Capital Management.
Founded in 2016, Dynacure is preparing for phase 1/2 clinical testing on a drug candidate…
